Jorge Mena
Family · Lafayette, LANPI 1891233037
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Rigel Pharmaceuticals, Inc. accounts for 75.3% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2022 at $15,679 and has fallen 86.9% since, to $2,052 in 2025. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $173.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rigel Pharmaceuticals, Inc.$20K
- Novartis$2K
- AstraZeneca$1K
- CTI Biopharma Corp.$700
- Incyte Corporation$590
- Sobi, Inc$175
- plus $2K from 32 others
What the payments were for
- Consulting fees$8,38431%
- Speaking & faculty fees$9,92836%
- Travel & lodging$3,09211%
- Food & beverage$2,89511%
- Education$7053%
- Other$2,1968%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rigel Pharmaceuticals, Inc. | 29 | $20,474 |
| Novartis | 37 | $2,487 |
| AstraZeneca | 17 | $1,265 |
| CTI Biopharma Corp. | 1 | $700 |
| Incyte Corporation | 10 | $590 |
| Sobi, Inc | 3 | $175 |
| Sanofi-aventis U.S. LLC | 2 | $150 |
| Sanofi | 4 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $98 |
| Daiichi Sankyo Inc. | 4 | $96 |
| Johnson & Johnson | 4 | $95 |
| Pfizer | 5 | $94 |
| Merck | 4 | $88 |
| Apellis Pharmaceuticals, Inc. | 1 | $71 |
| Genentech USA, Inc. | 3 | $68 |
| AbbVie | 3 | $68 |
| Stemline Therapeutics Inc. | 3 | $62 |
| Exelixis Inc. | 2 | $51 |
| Boston Scientific | 1 | $37 |
| Eisai Inc. | 2 | $35 |
| Ipsen Biopharmaceuticals, Inc | 1 | $30 |
| Puma Biotechnology, Inc. | 1 | $28 |
| Tempus AI, Inc | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $24 |
| Bristol Myers Squibb | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Springworks Therapeutics, Inc. | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| Beone Medicines USA, Inc. | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
| AVEO Pharmaceuticals, Inc. | 1 | $17 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Bayer | 1 | $14 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,201 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumakrasSotorasib | 11 | $207,250 |
| CalquenceAcalabrutinib Maleate | 12 | $187,272 |
| EliquisApixaban | 69 | $56,544 |
| Imatinib Mesylate | 21 | $41,032 |
| XareltoRivaroxaban | 16 | $26,337 |
| Hydroxyurea | 38 | $1,345 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 22 | $1,112 |
| Mirtazapine | 52 | $665 |
| Gabapentin | 32 | $604 |
| Levothyroxine Sodium | 76 | $513 |
| Anastrozole | 27 | $396 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $339 |
| Ondansetron Hcl | 21 | $312 |
| Folic Acid | 31 | $250 |
| Prednisone | 42 | $193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $1,265 | $187,27212 claims |
| PfizerEliquis | $94 | $56,54469 claims |
| Johnson & JohnsonXarelto | $95 | $26,33716 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $51376 claims |
| Lilly USA, LLCOlanzapine | $18 | $14013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Lafayette
- Rebekah GarrardLafayette$105K
- Amanda KeysLafayette$27K
- Shanna JohnsonLafayette$22K
- Layne LemaireLafayette$13K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.